丹麦,诺和诺德,Novo Nordisk, www.novonordisk.com  www.novonordisk.com.cn   
诺和诺德（Novo Nordisk，OMX: NOVO B, NYSE: NVO）是世界领先的生物制药公司，在用于糖尿病治疗的胰岛素开发和生产方面居世界领先地位。诺和诺德总部位于丹麦首都哥本哈根，员工总数18,000人，分布于70个国家，产品销售遍布179个国家。在欧美均建有生产厂。

诺和诺德的历史最早可追溯至1923年。近80年来，诺和诺德不断运用先进的生物技术完善胰岛素研究和生产手段，取得突破性进展，成为这一领域的先驱。诺和诺德率先推出长效胰岛素，预混胰岛素，高纯胰岛素，人体胰岛素和胰岛素注射笔。同时，诺和诺德又率先推出新一类的口服降糖药-诺和龙，从而极大地提高了糖尿病治疗和控制水平，改善了糖尿病人的生活质量。此外，诺和诺德还在凝血治疗、生长保健以及激素替代疗法等很多方面居世界领先地位。

诺和诺德的产品60年代初就已进入中国市场。1994年初，诺和诺德董事会通过了在中国实施战略投资的计划，在北京建立诺和诺德（中国）制药有限公司总部和生物技术研究发展中心，并在天津兴建现代化生产工厂。

诺和诺德的标志是古埃及动物Apis公牛，它被看成是掌管科学和艺术之神-Ptah的化身，象征着生命和健康。公司标志是1925年根据一尊公元前600 年的古埃及青铜雕像设计的。诺和诺德公司选用Apis公牛作为标志，象征着公司继承和发扬几百年来药学家和化学家努力进取，不断探索的古老传统。

主要产品：人胰岛素系列－诺和灵 诺和针 诺和英 诺和笔；新一代速效胰岛素注射液 诺和锐；促胰岛素分泌剂 诺和龙；人胰高血糖素诺和生

糖尿病服务信息 诺和关怀咨询服务热线：
8008102299/4008102299/65388866
诺和诺德(中国)制药有限公司
北京市朝阳区东三环中路1号环球金融中心东楼18层
邮编：100020
电话：+86 (010) 5961 5858
传真：+86 (010) 6505 6668 
诺和诺德糖尿病服务中心
北京市朝阳区东三环中路1号环球金融中心东楼17层
邮编：100020
电话：+86（10）6538 8866
传真：+86（10）6538 8282

Novo Nordisk is a global healthcare company with 87 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs more than 29,300 employees in 76 countries, and markets its products in 179 countries.
Novo Nordisk’s B shares are listed on the NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).

The Novo Nordisk logo
The Novo Nordisk logo is the Apis bull, one of the sacred animals of ancient Egypt.
The Apis bull was worshipped as the incarnation of Ptah, creator of the universe, city god of Memphis and the patron deity of craftsmen. 
The logo is a stylised reproduction of an Egyptian statuette dating from circa 664–323 BC. It is richly ornamented with symbols representing, among other things, the eternal dualities of life, day and night, life and death.
 
Already in 1923, Nordisk Insulinlaboratorium manufactured the first Scandinavian insulin product capable of saving the lives of people with diabetes. In 1925 Novo Terapeutisk Laboratorium was founded and started producing insulin and a special syringe for injecting it.
The Apis bull has been Novo's logo since the year after the foundation of Novo Terapeutisk Laboratorium.
The choice of the logo follows an old European chemist's tradition of identifying pharmacies by an animal symbol.
 
Novo Nordisk was created in 1989 through a merger between two Danish companies – Novo Industri A/S and Nordisk Gentofte A/S.
1923 Nordisk Insulinlaboratorium founded.
1925 Novo Terapeutisk Laboratorium founded.
1926 Nordisk establishes Nordisk Insulin Foundation with the object of supporting physiological and endocrinological research and people with diabetes in Scandinavia.
1932 Nordisk founds the Steno Memorial Hospital.
1938 Novo founds Hvidøre Diabetes Sanatorium.
1946 Nordisk develops isophane insulin (NPH), a neutral insulin with prolonged action.
1947 Penicillin Novo – Novo's first product to be manufactured through fermentation – is launched.
1951 Novo establishes the Novo Foundation with the object of supporting scientific, social and humanitarian causes and to provide the best possible protection for the company.
1953 Novo launches Lente® – a long-acting insulin–zinc suspension.
1973 Nordisk markets Nanormon® growth hormone for the treatment of growth hormone insufficiency. The growth hormone is extracted from human pituitary glands.
1973 Novo introduces Monocomponent (MC) insulin – the purest insulin available.
1974 Novo's B shares are quoted on the Copenhagen Stock Exchange.
1981 Novo becomes the first company in Scandinavia to be quoted on the New York Stock Exchange.
1982 Novo launches Human Monocomponent insulin – the world's first insulin preparation identical to human insulin. It is extracted from the pancreases of pigs and converted to human insulin.
1985 NovoPen® – an injection system similar in appearance to a fountain pen, with replaceable insulin cartridges – is launched.
1987 Novo starts production of human insulin with the help of genetic engineering.
1988 Novo markets Vagifem® – the first unique vaginal tablet for atrophic vaginitis.
1988 Nordisk markets Norditropin® genetically engineered human growth hormone.
1989 Nordisk Insulinlaboratorium, the Nordisk Insulin Foundation and the Novo Foundation merge to become the Novo Nordisk Foundation. The objects are to provide a stable basis for the Novo Group companies' operations and to support scientific causes.
1989 Novo Industri A/S and Nordisk Gentofte A/S merge to become Novo Nordisk A/S – the world's leading producer of insulin.
1989 NovoLet® – the world's first prefilled insulin syringe – is marketed.
1991 Novo Nordisk joins the environmental charter of the International Chamber of Commerce (ICC).
1992 The Steno Memorial Hospital and Hvidøre Hospital merge to form the Steno Diabetes Center.
1994 Novo Nordisk is the first company in Denmark – and one of the first in the world – to publish an environmental report.
1996 NovoSeven® – for the treatment of haemophilia patients with inhibitor reaction – is launched.
1998 NovoNorm® (Prandin® in the US) – a new oral treatment for type 2 diabetes – is launched in the US and a number of European countries.
1998 Activelle® (Activella® in the US) – the first low-dose continuous combined oral HRT for postmenopausal women – is introduced.
1999 Novo Nordisk publishes its first social report.
1999 NovoRapid® (NovoLog® in the US) – the company's first modern insulin, a rapid-acting insulin analogue – is marketed. Modern insulins are designed to better mimic the normal insulin response to changes in blood sugar levels.
1999 Norditropin® SimpleXx® – the world's first liquid growth hormone in a dedicated pen system – is launched.
2000 Novo Nordisk is split into three separate companies operating under the umbrella of the Novo Group: Novo Nordisk A/S, Novozymes A/S and Novo A/S.
2001 InnoLet® – the first insulin delivery system specially designed to suit the needs of insulin users with poor eyesight and reduced dexterity – is launched.
2001 Novo Nordisk establishes the World Diabetes Foundation with the purpose of improving diabetes care in developing countries.
2001 NovoRapid® FlexPen® is marketed. FlexPen® is a new prefilled pen, designed for easy and discreet use.
2002 Novo Nordisk signs the United Nations Global Compact, a platform for promoting good corporate principles and learning experiences in the areas of human rights, labour, environment and anti-corruption.
2002 NovoMix® 30 – a dual-release modern insulin – is introduced.
2003 Norditropin NordiFlex® – the world's first prefilled growth hormone pen – is launched.
2004 Levemir® – a long-acting modern insulin – is launched.
2004 Novo Nordisk's articles of association are amended to specify that the company will “strive to conduct its activities in a financially, environmentally and socially responsible way”.
2005 The Novo Nordisk Haemophilia Foundation is set up in response to the significant need to improve haemophilia treatment in the developing world, underlining the company's social responsibility within haemophilia care.
2006 Novo Nordisk signs an agreement with the World Wide Fund for Nature (WWF) that commits the company to reduce its carbon emissions by 10% by 2014 compared with 2004. Novo Nordisk is the 10th company in the world to join the WWF Climate Savers initiative.
2007 Activella® 0.5 mg/0.1 mg – the first ultra-low-dose oral HRT for women with menopausal symptoms – is launched in the US.
2007 In Montes Claros, Brazil, Novo Nordisk inaugurates its largest insulin production facility outside of Denmark.
2009 Victoza® - human Glucagon-Like Peptide (GLP-1) analogue for once-daily treatment of adults with type 2 diabetes - is launched in Europe.
Product names:
Not all products have been introduced worldwide. Trade names may vary from country to country.